TY - JOUR
T1 - Automated radiosynthesis of 5-[11C]L-glutamine, an important tracer for glutamine utilization
AU - Rosenberg, Adam J.
AU - Nickels, Michael L.
AU - Schulte, Michael L.
AU - Manning, H. Charles
N1 - Funding Information:
The authors would like to acknowledge Yiu-Yin Cheung PhD for experimental assistance. The authors wish to acknowledge research support from the Vanderbilt Ingram Cancer Center Support Grant (National Institutes of Health (NIH) National Cancer Institute (NCI) P30CA068485 ); the Kleberg Foundation ; a Vanderbilt Trans-Institutional Program (TIPS) Award to the Vanderbilt Center for Molecular Probes; and the Vanderbilt Digestive Disease Research Center (NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) P30DK058404 ); Shared Instrumentation Grant (NIH, 1S10OD019963 ).
Funding Information:
The authors would like to acknowledge Yiu-Yin Cheung PhD for experimental assistance. The authors wish to acknowledge research support from the Vanderbilt Ingram Cancer Center Support Grant (National Institutes of Health (NIH) National Cancer Institute (NCI) P30CA068485); the Kleberg Foundation; a Vanderbilt Trans-Institutional Program (TIPS) Award to the Vanderbilt Center for Molecular Probes; and the Vanderbilt Digestive Disease Research Center (NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) P30DK058404); Shared Instrumentation Grant (NIH, 1S10OD019963).
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/12
Y1 - 2018/12
N2 - Introduction: The natural amino acid L-Glutamine (Gln) is essential for both cell growth and proliferation. In addition to glucose, cancer cells utilize Gln as a carbon source for ATP production, biosynthesis, and as a defense against reactive oxygen species. The utilization of [11C]Gln has been previously reported as a biomarker for tissues with an elevated demand for Gln, however, the previous reports for the preparation of [11C]Gln were found to be lacking several crucial aspects necessary for transition to human production. Namely, the presence of unreacted precursor and the use of non-commercialized, custom built, reaction platforms. Herein, we report the development and utilization of methodology for the automated production of [11C]Gln that meets institutional criteria for human use. Methods: The preparation of [11C]Gln was carried out on the GE FX2N platform. Briefly, after trapping of [11C]HCN with a solution of CsHCO3 in DMF, the [11C]CsCN was reacted with a commercially available precursor. This intermediate was then purified by HPLC and deprotected/hydrolyzed under acidic conditions. Following pH adjustment, the product was filtered to give the desired [11C]Gln as a sterile injectable. The resulting product was then analyzed for quality assurance. Results: Automated production by this method reliably provides over 3.7 GBq (100 mCi) of [11C]Gln. The resulting final drug product was found to have a >99% radiochemical purity, <5% of D-Gln present, no detectable impurities, and the total preparation time was roughly 45 min from the end-of-bombardment. Conclusions: A fast, reliable and efficient automated radiosynthesis was developed using a commercially available module. Purifications used throughout allow for both a radiochemically and chemically pure final product solution of [11C]Gln.
AB - Introduction: The natural amino acid L-Glutamine (Gln) is essential for both cell growth and proliferation. In addition to glucose, cancer cells utilize Gln as a carbon source for ATP production, biosynthesis, and as a defense against reactive oxygen species. The utilization of [11C]Gln has been previously reported as a biomarker for tissues with an elevated demand for Gln, however, the previous reports for the preparation of [11C]Gln were found to be lacking several crucial aspects necessary for transition to human production. Namely, the presence of unreacted precursor and the use of non-commercialized, custom built, reaction platforms. Herein, we report the development and utilization of methodology for the automated production of [11C]Gln that meets institutional criteria for human use. Methods: The preparation of [11C]Gln was carried out on the GE FX2N platform. Briefly, after trapping of [11C]HCN with a solution of CsHCO3 in DMF, the [11C]CsCN was reacted with a commercially available precursor. This intermediate was then purified by HPLC and deprotected/hydrolyzed under acidic conditions. Following pH adjustment, the product was filtered to give the desired [11C]Gln as a sterile injectable. The resulting product was then analyzed for quality assurance. Results: Automated production by this method reliably provides over 3.7 GBq (100 mCi) of [11C]Gln. The resulting final drug product was found to have a >99% radiochemical purity, <5% of D-Gln present, no detectable impurities, and the total preparation time was roughly 45 min from the end-of-bombardment. Conclusions: A fast, reliable and efficient automated radiosynthesis was developed using a commercially available module. Purifications used throughout allow for both a radiochemically and chemically pure final product solution of [11C]Gln.
KW - Automated radiosynthesis
KW - Carbon-11
KW - Metabolism
KW - PET
KW - Radiopharmaceuticals
KW - [C]Glutamine
UR - http://www.scopus.com/inward/record.url?scp=85055164775&partnerID=8YFLogxK
U2 - 10.1016/j.nucmedbio.2018.09.002
DO - 10.1016/j.nucmedbio.2018.09.002
M3 - Article
C2 - 30359787
AN - SCOPUS:85055164775
SN - 0969-8051
VL - 67
SP - 10
EP - 14
JO - Nuclear Medicine and Biology
JF - Nuclear Medicine and Biology
ER -